- Home
- BBIO vs OCEAW Comparison
BBIO vs OCEAW Comparison
Compare BBIO & OCEAW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BBIO
- OCEAW
- Stock Information
- Founded
- BBIO 2015
- OCEAW N/A
- Country
- BBIO United States
- OCEAW United States
- Employees
- BBIO N/A
- OCEAW 7
- Industry
- BBIO Biotechnology: Pharmaceutical Preparations
- OCEAW Biotechnology: Pharmaceutical Preparations
- Sector
- BBIO Health Care
- OCEAW Health Care
- Exchange
- BBIO Nasdaq
- OCEAW Nasdaq
- Market Cap
- BBIO N/A
- OCEAW N/A
- IPO Year
- BBIO 2019
- OCEAW 2021
- Fundamental
- Price
- BBIO $33.87
- OCEAW $0.02
- Analyst Decision
- BBIO Strong Buy
- OCEAW
- Analyst Count
- BBIO 12
- OCEAW 0
- Target Price
- BBIO $53.00
- OCEAW N/A
- AVG Volume (30 Days)
- BBIO 2.8M
- OCEAW N/A
- Earning Date
- BBIO 05-01-2025
- OCEAW N/A
- Dividend Yield
- BBIO N/A
- OCEAW N/A
- EPS Growth
- BBIO N/A
- OCEAW N/A
- EPS
- BBIO N/A
- OCEAW N/A
- Revenue
- BBIO $221,902,000.00
- OCEAW N/A
- Revenue This Year
- BBIO $14.88
- OCEAW N/A
- Revenue Next Year
- BBIO $121.23
- OCEAW N/A
- P/E Ratio
- BBIO N/A
- OCEAW N/A
- Revenue Growth
- BBIO 2285.27
- OCEAW N/A
- 52 Week Low
- BBIO $21.62
- OCEAW N/A
- 52 Week High
- BBIO $39.47
- OCEAW N/A
- Technical
- Relative Strength Index (RSI)
- BBIO 51.06
- OCEAW N/A
- Support Level
- BBIO $33.10
- OCEAW N/A
- Resistance Level
- BBIO $35.16
- OCEAW N/A
- Average True Range (ATR)
- BBIO 2.25
- OCEAW 0.00
- MACD
- BBIO 0.09
- OCEAW 0.00
- Stochastic Oscillator
- BBIO 78.71
- OCEAW 0.00
About OCEAW Ocean Biomediacal Inc.
Ocean Biomedical Inc is a biopharmaceutical company that is focused on discovering and developing therapeutic products in oncology, fibrosis, and infectious diseases. The company is developing an antibody therapeutic product candidate inhibiting Chi3l1, and a bi-specific antibody product candidate inhibiting Chi3l1 plus PD-1 and CTLA-4 for the treatment of non-small cell lung cancer and glioblastoma multiforme; and a small molecule product candidate targeting Chit1 for the treatment of Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome.